# miRNA expression profile as a potential tool for discrimination between bacterial and interstitial cystitis

**Authors:** Dominika Peskar, Nika Kojc, Andreja Erman, Emanuela Boštjančič

PMC · DOI: 10.3389/fimmu.2026.1738839 · Frontiers in Immunology · 2026-02-16

## TL;DR

This study explores miRNA expression in mouse models to distinguish between bacterial and interstitial cystitis, identifying potential biomarkers and therapeutic targets.

## Contribution

The study identifies miR-301a-3p as a potential biomarker for differentiating IC from BC and highlights its target gene NKRF.

## Key findings

- 20 of 33 selected miRNAs showed differential expression in IC and BC compared to controls.
- miR-301a-3p and its target gene NKRF were identified as potential markers for distinguishing IC from BC.
- Mouse IC models showed similarities to human IC, validating their use for studying IC mechanisms.

## Abstract

Interstitial cystitis (IC) is an aseptic chronic bladder inflammation of unknown etiology and poorly understood pathophysiology with symptoms resembling bacterial cystitis (BC). There is limited data about the contribution of regulatory microRNAs (miRNAs) in IC. The study aimed to identify differences in miRNA expression between mouse models of IC and BC to find potential miRNAs that would distinguish between the two types of cystitis and to evaluate the use of the mouse model of IC as a tool to study the pathogenic mechanisms of IC in humans.

Two mouse models were utilized: cyclophosphamide was used for induction of chronic aseptic cystitis, and uropathogenic E.coli for induction of acute bacterial cystitis. Potential regulatory miRNAs were selected based on publicly available human IC datasets and validated in mice. Quantitative PCR and RNA isolated from formalin-fixed, paraffin-embedded mouse bladder tissue were used. An enrichment analysis of the target mRNAs of the validated miRNAs was performed to suggest the differences in the possible mechanisms of inflammation between the IC and BC.

We observed differential expression of 20 of the 33 selected miRNAs in IC and BC compared to the control group, with 11 miRNAs showing the same trend of expression between mouse and human IC. There are 8 common reporter-assay (RA) validated targets (performed by others) of these miRNAs in mouse and human. Histopathological analysis of mouse IC and BC urinary bladders, miRNA expression analysis, and expression of their validated targets revealed significant differences between the urinary bladders of BC and IC mouse models. We identified miR-301a-3p as a possible marker of discrimination between two types of cystitis and its target gene, nuclear factor-κB (NF-κB) suppressing factor (NKRF).

Our results show that miRNA expression and its RA-validated targets, and enriched signaling pathways, differ between the two types of cystitis and might depend on the type of bladder inflammation. The mouse model of IC has some similarities with human IC, confirming that it is a useful tool to identify novel potentially discriminatory biomarkers between BC and IC, such as miR-301a-3p, and also potential therapeutic targets for IC (e.g., NKRF and NF-κB).

## Linked entities

- **Genes:** NKRF (NFKB repressing factor) [NCBI Gene 55922]
- **Chemicals:** cyclophosphamide (PubChem CID 2907)
- **Diseases:** interstitial cystitis (MONDO:0018301)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Runx3 (runt related transcription factor 3) [NCBI Gene 12399] {aka AML2, Cbfa3, Pebp2a3, Rx3}, Grip2 (glutamate receptor interacting protein 2) [NCBI Gene 243547], Mir146 (microRNA 146) [NCBI Gene 387164] {aka Mirn146, miR-146a, mmu-mir-146}, Mir133b (microRNA 133b) [NCBI Gene 723817] {aka Mirn133b, mir-133b}, Smad4 (SMAD family member 4) [NCBI Gene 17128] {aka D18Wsu70e, DPC4, Madh4}, Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, Sirt1 (sirtuin 1) [NCBI Gene 93759] {aka SIR2L1, Sir2, Sir2a, Sir2alpha}, Trp53-ps (transformation related protein 53, pseudogene) [NCBI Gene 22060], Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Rb1 (RB transcriptional corepressor 1) [NCBI Gene 19645] {aka Rb, Rb-1, p110-RB1, pRb, pp105}, Mir20b (microRNA 20b) [NCBI Gene 723923] {aka Mirn20b, mir-20b, mmu-mir-20b}, Mir375 (microRNA 375) [NCBI Gene 723900] {aka Mirn375, mir-375, mmu-mir-375}, Socs5 (suppressor of cytokine signaling 5) [NCBI Gene 56468] {aka 1810018L08Rik, Cish5, mKIAA0671}, Nts (neurotensin) [NCBI Gene 67405] {aka 5033428E16Rik, NMN-125, NN, NT, NT/N, NTS1}, Nkrf (NF-kappaB repressing factor) [NCBI Gene 77286] {aka 9430034D17Rik}, Tlr7 (toll-like receptor 7) [NCBI Gene 170743], Mir320 (microRNA 320) [NCBI Gene 723838] {aka Mirn320, mir-320, mmu-mir-320}, Dll1 (delta like canonical Notch ligand 1) [NCBI Gene 13388] {aka Delta1}, Traf6 (TNF receptor-associated factor 6) [NCBI Gene 22034] {aka 2310003F17Rik, C630032O20Rik}, Tub (TUB bipartite transcription factor) [NCBI Gene 22141] {aka rd5}, E2f1 (E2F transcription factor 1) [NCBI Gene 13555] {aka E2F-1, Tg(Wnt1-cre)2Sor, mKIAA4009}, Ifnb1 (interferon beta 1, fibroblast) [NCBI Gene 15977] {aka IFN-beta, IFNB, If1da1, Ifb}, Hgf (hepatocyte growth factor) [NCBI Gene 15234] {aka C230052L06Rik, HGF/SF, NK1, NK2, SF, SF/HGF}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Cd14 (CD14 antigen) [NCBI Gene 12475], Gja3 (gap junction protein, alpha 3) [NCBI Gene 14611] {aka Cnx46, Cx43, Cx46, Cxnj1, Gja-3}, Btg1 (BTG anti-proliferation factor 1) [NCBI Gene 12226], Mir326 (microRNA 326) [NCBI Gene 723840] {aka Mirn326, mir-326, mmu-mir-326}, Stat1 (signal transducer and activator of transcription 1) [NCBI Gene 20846] {aka 2010005J02Rik}, Tacr1 (tachykinin receptor 1) [NCBI Gene 21336] {aka Nk1r, Spr, Tac1r}, Prkaa1 (protein kinase, AMP-activated, alpha 1 catalytic subunit) [NCBI Gene 105787] {aka AMPKalpha1, C130083N04Rik}, E2f2 (E2F transcription factor 2) [NCBI Gene 242705] {aka E2F-2}, Pten (phosphatase and tensin homolog) [NCBI Gene 19211] {aka 2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, PTENbeta, TEP1}, Mir10b (microRNA 10b) [NCBI Gene 387144] {aka Mirn10b, mir-10b, mmu-mir-10b}, Smo (smoothened, frizzled class receptor) [NCBI Gene 319757] {aka E130215L21Rik, Smoh, bnb, smoothened}, Bcl2l11 (BCL2 like 11) [NCBI Gene 12125] {aka 1500006F24Rik, Bim, Bod, bcl2-L-11}, Mir19a (microRNA 19a) [NCBI Gene 723891] {aka Mirn19a, mir-19a, mmu-mir-19a}, Mir495 (microRNA 495) [NCBI Gene 751522] {aka Mirn495, mir-495, mmu-mir-495}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Irak1 (interleukin-1 receptor-associated kinase 1) [NCBI Gene 16179] {aka IRAK, IRAK-1, IRAK1-S, IRAK1b, Il1rak, Plpk}, Fxr1 (FMR1 autosomal homolog 1) [NCBI Gene 14359] {aka 1110050J02Rik, 9530073J07Rik, Fxr1h, Fxr1p}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Scn2b (sodium channel, voltage-gated, type II, beta) [NCBI Gene 72821] {aka 2810451E09Rik, Gm183}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Jak1 (Janus kinase 1) [NCBI Gene 16451] {aka BAP004, C130039L05Rik}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Myc (Myc proto-oncogene, bHLH transcription factor) [NCBI Gene 17869] {aka Myc2, Niard, Nird, bHLHe39}, Mir301 (microRNA 301) [NCBI Gene 723834] {aka Mirn301, mir-301a, mmu-mir-301}, Elavl1 (ELAV like RNA binding protein 1) [NCBI Gene 15568] {aka 2410055N02Rik, HUR, Hua}, Mir381 (microRNA 381) [NCBI Gene 723935] {aka Mirn381, mir-381, mmu-mir-381}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Mir145a (microRNA 145a) [NCBI Gene 387163] {aka Mir145, Mirn145, mir-145a, mmu-mir-145, mmu-mir-145a}, Snhg12 (small nucleolar RNA host gene 12) [NCBI Gene 100039864] {aka 2310005L22Rik}, Eif3j1 (eukaryotic translation initiation factor 3, subunit J1) [NCBI Gene 78655] {aka 1810016I04Rik, 2700079K05Rik, Eif3j, Eif3j-1, Eif3j-2, Eif3j2}, Jak3 (Janus kinase 3) [NCBI Gene 16453] {aka fae, wil}, Akt3 (Akt serine/threonine kinase 3) [NCBI Gene 23797] {aka D930002M15Rik, Nmf350}, Notch1 (notch 1) [NCBI Gene 18128] {aka 9930111A19Rik, Mis6, N1, Tan1, lin-12}, Mir204 (microRNA 204) [NCBI Gene 387200] {aka Mirn204, mir-204, mmu-mir-204}, Irf1 (interferon regulatory factor 1) [NCBI Gene 16362] {aka Irf-1}
- **Diseases:** cystitis (MESH:D003556), inflammatory bladder disease (MESH:D001745), nocturia (MESH:D053158), cancer (MESH:D009369), edema (MESH:D004487), Inflammatory (MESH:D007249), bladder fibrosis (MESH:D005355), pain (MESH:D010146), hematuria (MESH:D006417), hyperalgesia (MESH:D006930), LUTDs (MESH:D014570), bladder cancer (MESH:D001749), inflammatory cytokines (MESH:D000080424), HIC (MESH:D018856), BC (MESH:D001424), Breast cancer (MESH:D001943), infection (MESH:D007239), Endocrine (MESH:D004700), UTI (MESH:D014552), asphyxia (MESH:D001237), ulcerative (MESH:D014456), pelvic pain (MESH:D017699)
- **Chemicals:** cyclophosphamide (MESH:D003520), water (MESH:D014867), mineral oil (MESH:D008899), paraffin (MESH:D010232), eosin (MESH:D004801), formalin (MESH:D005557), CO2 (MESH:D002245), LPS (MESH:D008070), BC (-), Thioglycerol (MESH:C009465), H&amp;E (MESH:D006371), NO (MESH:D009614), hematoxylin (MESH:D006416)
- **Species:** Escherichia coli UTI89 (strain) [taxon 364106], Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615], Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950535/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950535/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950535/full.md

---
Source: https://tomesphere.com/paper/PMC12950535